A multicenter retrospective study investigating the safety and efficacy of immune checkpoint inhibitors in lung cancer with interstitial pneumonia
Not Applicable
Recruiting
- Conditions
- ung cancer with interstitial pneumonia
- Registration Number
- JPRN-UMIN000043974
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Radiation pneumonia 2) Drug-induced pneumonia 3) Interstitial lung abnormality
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of drug-induced lung injury as an immune-related adverse event and rate of serious adverse events in patients treated with immune checkpoint inhibitors for primary lung cancer with interstitial pneumonia
- Secondary Outcome Measures
Name Time Method 1) Response rate of immune checkpoint inhibitors 2) Progression-free survival 3) Overall survival 4) Duration of treatment